The FDA has set the standard
that will make Clearant, Inc. (CLRI) shareholders rich
The all-powerful U.S. Food & Drug Administration (FDA) has issued the regulations on sterilized tissue that gives Clearant control of the multi-$Billion transplant industry
Buy CLRI now up to $5:
Now, the transplant of ligaments, tendons, and bones must adhere to the FDA’s Good Tissue Practice regulations to qualify as sterile procedures.
Now, every doctor, hospital, and insurance company must ensure that they meet these FDA regulations to avoid devastating lawsuits.
NOW, Clearant, Inc. (CLRI) is the only biotech company I’ve found to have the proven and proprietary technology to ensure that transplanted human tissues are safely sterile à VAST FORTUNES will be created for early CLRI shareholders.
The company’s Clearant Process® will ultimately dominate the entire transplant and vaccine industries because Clearant’s proprietary technology can prevent more than just bacterial and viral infections – it arguably can stop the transfer of “Mad Cow” disease and Hepatitis.
FDA approval is the key to your CLRI stock-fortune
Although the Food & Drug Administration’s mission statement doesn’t include making stock recommendations, billions of dollars of investor wealth have been created as a result of fortunate companies gaining FDA favor and approval. Immense fortunes – such as in Pfizer upon the approval of Viagra – can be made by closely monitoring the FDA and preemptively buying the next low-profile stock to be propelled upward before the powerful approval is granted. Clearant, Inc. (CLRI) is the next stock to receive this favor.
Future CLRI shareholder wealth from lessons of past tragedy
The transplant of soft tissues, such as ligaments and tendons, from living or deceased donors always entails a degree of unavoidable risk for the recipient. Historically, the debilitating and sometimes deadly transfer of bacterial and viral infections was considered part of the unavoidable risk factor. The public outcry after a well publicized post-transplant death pushed the FDA to respond.
In 2001, national news coverage on the death of a 23-year-old Minnesota man just after a bone-cartilage transplant prompted a comprehensive investigation by the Centers for Disease Control (CDC). The final report to the Food and Drug Administration revealed a serious escalation in transplant-related infections caused by improperly sterilized tissue. To prevent a potentially devastating epidemic, the FDA issued its Good Tissue Practice (GTP) regulations in November 2004. The GTP regulations set the requirements for all transplantable tissue to be officially declared as sterilized.
IMPORTANT: The Food & Drug Administration’s GTP regulations on sterilized human tissue for transplant will become mandatory at any moment – and your Clearant (CLRI) share-value will go straight up. Buy CLRI Now.
Clearant’s captive market is now every doctor, hospital, and insurance company in the transplant business
As soon as tomorrow, the FDA could announce that the grace-period for adherence to its Good Tissue Practice regulations is over – signaling immediate, mandatory GTP regulations on all soft human-tissue transfers. For a tissue bank to stamp a ligament or tendon, prepped for transplant, as officially sterilized according to FDA regulations, the Clearant Process® must be applied.
In our uncertain world, I can confidently guarantee you this: No doctor, hospital, or insurance company – in their right mind – would risk total lawsuit devastation by allowing the use of non-FDA approved human tissue in a medical procedure.
Now, here’s the crucial point that will make you vast amounts of money as an early Clearant (CLRI) shareholder: My in-depth research has revealed that only one company has the sterilization technology to meet FDA regulations while still preserving the functionality of the transplanted tissue – Clearant (CLRI) must be bought now up to $5.
The Clearant Process® is already a proven success and has no competition
Even before the FDA issued its Good Tissue Practice regulations in November 2004, Clearant was systematically proving the effectiveness of its proprietary tissue sterilization technology. The company’s reports on more than 2,000 successful patient implants of clean tissue since January 2004 is the strongest buy-signal I’ve seen from an emerging biotech stock in over 10 years. In fact, Clearant has already recorded royalties from the six licenses, granted to date, to utilize the Clearant Process®. The secret on Clearant will soon be out and the CLRI share price will soon be way up -- Buy CLRI now below $5.
Here’s the technology in basic form…so you’ll still have time to place your buy order on CLRI before the end of the market day:
The Clearant Process® is based on treating human tissue before transplantation with gamma-irradiation under specialized, proprietary and/or patented conditions that deliver a predetermined amount of radiation to prevent the transfer of bacterial or viral infection while preserving the functionality of the transplanted tissue. The old method in the transplant industry relied upon chemically washing tissue before transplant – but Clearant has rendered this archaic practice obsolete.
All the technical data is available at www.Clearant.com or by calling 310-479-4570 for those among us who wear white lab coats for a living. For now, my immediate objective is for all my fellow Contrarians to own CLRI while it is still trading below $5. Once the Food & Drug Administration announces that its GTP regulations on officially sterilized tissue are mandatory, your CLRI share-value will be driven multiples higher by the reactive market.
By buying CLRI now, you will own a piece of the Clearant Process®. Clearant has set the new, mandatory standard in sterilized safety during in-tissue transplants, which will inevitably become the standard for all transplant processes for vaccines, blood, bone, and someday even genetic material. By solving a long-standing and pervasive medical-industry problem, Clearant will make its early shareholders very wealthy.
CLRI will deliver even greater profits upon its upward move to the American Stock Exchange (Amex)
At the start of 2005, I promised you, my fellow Contrarians, a biotech-stock recommendation that would deliver historic profits as this sector re-emerges to public favor. The company is Clearant, Inc. (CLRI) -- I recommend that you buy the stock immediately and continue accumulating up to my initial buy ceiling of $5.00. Within weeks, Clearant will no longer be a secret, major institutional buying will start driving the share price upward, and all CLRI shares currently available under $5 will be long gone.
YOU can buy Clearant NOW
BEFORE Wall Street's powerhouses and before Clearant’s Amex listing deliver substantially improved liquidity and an expanded market profile. I expect the company to complete its upward listing transition by mid-July.
My near-term profit target, set at the $10 level, recently became a virtual lock when Clearant announced its commitment to an American Stock Exchange listing on 19 May. Right now, a select group of Wall Street institutions are already aware that Clearant is the number one biotech stock to buy in 2005 based on profit probabilities. But, they must wait until CLRI moves up from the bulletin-board exchange to the Amex before taking a substantial Clearant share position.
I will provide you with my full, comprehensive analysis on Clearant as soon as possible…but I want you to start accumulating CLRI now before this white-hot biotech story becomes financial newswire headlines. This could happen at any moment. My forthcoming report will present a detailed outline of Clearant’s technological corner on the immense tissue sterilization industry. As mentioned, the FDA is setting guidelines for sterilization to which every doctor, hospital, and insurance company must adhere – and the great news for us is that Clearant is the only biotech company I’ve found that enables this required adherence. Translation: Clearant’s revenues will be huge.
My buy recommendation on Clearant, Inc. (CLRI) should be followed immediately up to $5 a share. And keep in mind that my initial share-price target of $10 is just the tip of our future CLRI profits as the FDA continues to expand the scope of its Good Tissue Practice (GTP) mandates on transplants and transfusions.
Get YOUR Arsenal of Automatic-Profit Weapons
At the end of this report is an offer for you to obtain my proprietary stock-selection system – The Arsenal of Automatic-Profit Weapons. This system contains the exact tools I have used for over a decade to compile my list of legendary profit-stocks. Once you own this system, you’ll be able to deploy it forever for your own profitable reward.
Sincerely on the Contrary,
Scott S. Fraser
Click here for more information on The Natural Contrarian.
--------------------------------------------------
THE NATURAL CONTRARIAN
1155 Camino Del Mar, No. 468 • Del Mar, CA 92014
www.NaturalContrarian.com • E-mail: info@NaturalContrarian.com
that will make Clearant, Inc. (CLRI) shareholders rich
The all-powerful U.S. Food & Drug Administration (FDA) has issued the regulations on sterilized tissue that gives Clearant control of the multi-$Billion transplant industry
Buy CLRI now up to $5:
Now, the transplant of ligaments, tendons, and bones must adhere to the FDA’s Good Tissue Practice regulations to qualify as sterile procedures.
Now, every doctor, hospital, and insurance company must ensure that they meet these FDA regulations to avoid devastating lawsuits.
NOW, Clearant, Inc. (CLRI) is the only biotech company I’ve found to have the proven and proprietary technology to ensure that transplanted human tissues are safely sterile à VAST FORTUNES will be created for early CLRI shareholders.
The company’s Clearant Process® will ultimately dominate the entire transplant and vaccine industries because Clearant’s proprietary technology can prevent more than just bacterial and viral infections – it arguably can stop the transfer of “Mad Cow” disease and Hepatitis.
FDA approval is the key to your CLRI stock-fortune
Although the Food & Drug Administration’s mission statement doesn’t include making stock recommendations, billions of dollars of investor wealth have been created as a result of fortunate companies gaining FDA favor and approval. Immense fortunes – such as in Pfizer upon the approval of Viagra – can be made by closely monitoring the FDA and preemptively buying the next low-profile stock to be propelled upward before the powerful approval is granted. Clearant, Inc. (CLRI) is the next stock to receive this favor.
Future CLRI shareholder wealth from lessons of past tragedy
The transplant of soft tissues, such as ligaments and tendons, from living or deceased donors always entails a degree of unavoidable risk for the recipient. Historically, the debilitating and sometimes deadly transfer of bacterial and viral infections was considered part of the unavoidable risk factor. The public outcry after a well publicized post-transplant death pushed the FDA to respond.
In 2001, national news coverage on the death of a 23-year-old Minnesota man just after a bone-cartilage transplant prompted a comprehensive investigation by the Centers for Disease Control (CDC). The final report to the Food and Drug Administration revealed a serious escalation in transplant-related infections caused by improperly sterilized tissue. To prevent a potentially devastating epidemic, the FDA issued its Good Tissue Practice (GTP) regulations in November 2004. The GTP regulations set the requirements for all transplantable tissue to be officially declared as sterilized.
IMPORTANT: The Food & Drug Administration’s GTP regulations on sterilized human tissue for transplant will become mandatory at any moment – and your Clearant (CLRI) share-value will go straight up. Buy CLRI Now.
Clearant’s captive market is now every doctor, hospital, and insurance company in the transplant business
As soon as tomorrow, the FDA could announce that the grace-period for adherence to its Good Tissue Practice regulations is over – signaling immediate, mandatory GTP regulations on all soft human-tissue transfers. For a tissue bank to stamp a ligament or tendon, prepped for transplant, as officially sterilized according to FDA regulations, the Clearant Process® must be applied.
In our uncertain world, I can confidently guarantee you this: No doctor, hospital, or insurance company – in their right mind – would risk total lawsuit devastation by allowing the use of non-FDA approved human tissue in a medical procedure.
Now, here’s the crucial point that will make you vast amounts of money as an early Clearant (CLRI) shareholder: My in-depth research has revealed that only one company has the sterilization technology to meet FDA regulations while still preserving the functionality of the transplanted tissue – Clearant (CLRI) must be bought now up to $5.
The Clearant Process® is already a proven success and has no competition
Even before the FDA issued its Good Tissue Practice regulations in November 2004, Clearant was systematically proving the effectiveness of its proprietary tissue sterilization technology. The company’s reports on more than 2,000 successful patient implants of clean tissue since January 2004 is the strongest buy-signal I’ve seen from an emerging biotech stock in over 10 years. In fact, Clearant has already recorded royalties from the six licenses, granted to date, to utilize the Clearant Process®. The secret on Clearant will soon be out and the CLRI share price will soon be way up -- Buy CLRI now below $5.
Here’s the technology in basic form…so you’ll still have time to place your buy order on CLRI before the end of the market day:
The Clearant Process® is based on treating human tissue before transplantation with gamma-irradiation under specialized, proprietary and/or patented conditions that deliver a predetermined amount of radiation to prevent the transfer of bacterial or viral infection while preserving the functionality of the transplanted tissue. The old method in the transplant industry relied upon chemically washing tissue before transplant – but Clearant has rendered this archaic practice obsolete.
All the technical data is available at www.Clearant.com or by calling 310-479-4570 for those among us who wear white lab coats for a living. For now, my immediate objective is for all my fellow Contrarians to own CLRI while it is still trading below $5. Once the Food & Drug Administration announces that its GTP regulations on officially sterilized tissue are mandatory, your CLRI share-value will be driven multiples higher by the reactive market.
By buying CLRI now, you will own a piece of the Clearant Process®. Clearant has set the new, mandatory standard in sterilized safety during in-tissue transplants, which will inevitably become the standard for all transplant processes for vaccines, blood, bone, and someday even genetic material. By solving a long-standing and pervasive medical-industry problem, Clearant will make its early shareholders very wealthy.
CLRI will deliver even greater profits upon its upward move to the American Stock Exchange (Amex)
At the start of 2005, I promised you, my fellow Contrarians, a biotech-stock recommendation that would deliver historic profits as this sector re-emerges to public favor. The company is Clearant, Inc. (CLRI) -- I recommend that you buy the stock immediately and continue accumulating up to my initial buy ceiling of $5.00. Within weeks, Clearant will no longer be a secret, major institutional buying will start driving the share price upward, and all CLRI shares currently available under $5 will be long gone.
YOU can buy Clearant NOW
BEFORE Wall Street's powerhouses and before Clearant’s Amex listing deliver substantially improved liquidity and an expanded market profile. I expect the company to complete its upward listing transition by mid-July.
My near-term profit target, set at the $10 level, recently became a virtual lock when Clearant announced its commitment to an American Stock Exchange listing on 19 May. Right now, a select group of Wall Street institutions are already aware that Clearant is the number one biotech stock to buy in 2005 based on profit probabilities. But, they must wait until CLRI moves up from the bulletin-board exchange to the Amex before taking a substantial Clearant share position.
I will provide you with my full, comprehensive analysis on Clearant as soon as possible…but I want you to start accumulating CLRI now before this white-hot biotech story becomes financial newswire headlines. This could happen at any moment. My forthcoming report will present a detailed outline of Clearant’s technological corner on the immense tissue sterilization industry. As mentioned, the FDA is setting guidelines for sterilization to which every doctor, hospital, and insurance company must adhere – and the great news for us is that Clearant is the only biotech company I’ve found that enables this required adherence. Translation: Clearant’s revenues will be huge.
My buy recommendation on Clearant, Inc. (CLRI) should be followed immediately up to $5 a share. And keep in mind that my initial share-price target of $10 is just the tip of our future CLRI profits as the FDA continues to expand the scope of its Good Tissue Practice (GTP) mandates on transplants and transfusions.
Get YOUR Arsenal of Automatic-Profit Weapons
At the end of this report is an offer for you to obtain my proprietary stock-selection system – The Arsenal of Automatic-Profit Weapons. This system contains the exact tools I have used for over a decade to compile my list of legendary profit-stocks. Once you own this system, you’ll be able to deploy it forever for your own profitable reward.
Sincerely on the Contrary,
Scott S. Fraser
Click here for more information on The Natural Contrarian.
--------------------------------------------------
THE NATURAL CONTRARIAN
1155 Camino Del Mar, No. 468 • Del Mar, CA 92014
www.NaturalContrarian.com • E-mail: info@NaturalContrarian.com
